Payment overview · 2025
General Payments
$1,222.74
52 reported records · 14 companies
Healthcare provider profile · identity verified
Malvin Yan, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · SOUTH GATE, CA · NPI 1033153101
Verified facts
What the public records show
CMS Open Payments records show Malvin Yan, D.O. received $1,222.74 in general payments during 2025 across 52 reported records.
Amgen Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Rayaldee.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rayaldee by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $329.03 | 26.9% | 20 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $218.44 | 17.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $129.93 | 10.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $104.50 | 8.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.48 | 6.2% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $62.27 | 5.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.17 | 4.3% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $49.44 | 4.0% | 3 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $48.33 | 4.0% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $40.47 | 3.3% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $39.35 | 3.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.50 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.69 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.14 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,122.75 | 51 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $219.59 | 14 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $218.44 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $119.39 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $109.44 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.07 | 5 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $81.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.48 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $62.27 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $49.44 | 3 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $48.33 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $39.35 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $33.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $20.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 37 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
34 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 104 |
| Gabapentin | Gabapentin | 289 | 92 |
| Eliquis | Apixaban | 265 | 46 |
| Furosemide | Furosemide | 260 | 71 |
| Metformin Hcl | Metformin Hcl | 242 | 70 |
| Famotidine | Famotidine | 228 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 202 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 49 |
| Losartan Potassium | Losartan Potassium | 188 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 41 |
| Omeprazole | Omeprazole | 153 | 48 |
| Levetiracetam | Levetiracetam | 134 | 21 |
| Allopurinol | Allopurinol | 132 | 48 |
| Lisinopril | Lisinopril | 130 | 38 |
| Potassium Chloride | Potassium Chloride | 124 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 46 |
| Donepezil Hcl | Donepezil Hcl | 119 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 33 |
| Carvedilol | Carvedilol | 112 | 42 |
| Glipizide | Glipizide | 110 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 26 |
| Memantine Hcl | Memantine Hcl | 105 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 34 |
| Jardiance | Empagliflozin | 91 | 29 |
| Lactulose | Lactulose | 90 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 19 |
| Simvastatin | Simvastatin | 86 | 22 |
| Mirtazapine | Mirtazapine | 82 | 16 |
| Labetalol Hcl | Labetalol Hcl | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 31 |
| Divalproex Sodium | Divalproex Sodium | 73 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 27 |
| Trazodone Hcl | Trazodone Hcl | 72 | 17 |
| Pregabalin | Pregabalin | 71 | 14 |
| Risperidone | Risperidone | 69 | 11 |
| Nifedipine Er | Nifedipine | 65 | 25 |
| Cephalexin | Cephalexin | 63 | 45 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | suppressed |
| Januvia | Sitagliptin Phosphate | 61 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 60 | 14 |
| Latanoprost | Latanoprost | 60 | 12 |
| Clonidine Hcl | Clonidine Hcl | 59 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 59 | 20 |
| Midodrine Hcl | Midodrine Hcl | 59 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 28 |
| Alendronate Sodium | Alendronate Sodium | 56 | 15 |
| Megestrol Acetate | Megestrol Acetate | 56 | 25 |
| Farxiga | Dapagliflozin Propanediol | 55 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 55 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 14 |
| Finasteride | Finasteride | 53 | 18 |
| Montelukast Sodium | Montelukast Sodium | 53 | suppressed |
| Baclofen | Baclofen | 52 | 14 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 52 | suppressed |
| Prosol | Parenteral Amino Acid 20% No.1 | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 48 | 20 |
| Lacosamide | Lacosamide | 46 | suppressed |
| Calcium Acetate | Calcium Acetate | 44 | 11 |
| Sucralfate | Sucralfate | 44 | 14 |
| Tramadol Hcl | Tramadol Hcl | 44 | 25 |
| Alprazolam | Alprazolam | 43 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 11 |
| Naproxen | Naproxen | 42 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 42 | 17 |
| Valsartan | Valsartan | 42 | 13 |
| Santyl | Collagenase Clostridium Hist. | 41 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Vascepa | Icosapent Ethyl | 40 | 13 |
| Brilinta | Ticagrelor | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 13 |
| Ertapenem | Ertapenem Sodium | 38 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Kerendia | Finerenone | 37 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | 15 |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | 15 |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 16 |
| Ketoconazole | Ketoconazole | 27 | 12 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Prednisone | Prednisone | 26 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | 12 |
| Invokana | Canagliflozin | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Enulose | Lactulose | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Rayaldee | Calcifediol | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 13 |
| Ozempic | Semaglutide | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ivermectin | Ivermectin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Darunavir | Darunavir | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,222.74 · 52 records | Amgen Inc. | ACTHAR, FARXIGA, Fabhalta, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, OTEZLA, RAYALDEE, REPATHA, REXULTI, TARPEYO, VELPHORO, VOYXACT, Vafseo | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error